Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review

  title={Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review},
  author={G. Brewer and S. Merajver},
  journal={Integrative Cancer Therapies},
  pages={327 - 337}
  • G. Brewer, S. Merajver
  • Published 2002
  • Medicine
  • Integrative Cancer Therapies
  • A new anticopper drug, tetrathiomolybdate (TM), developed for Wilson’s disease, is a very promising antiangiogenic agent. Copper levels lowered into an antiangiogenic window by TM have shown efficacy against cancer in a variety of animal models as well as in patients. The only significant toxicity so far results from over treatment and excessive bone marrow depletion of copper. The resulting anemia and/or leukopenia is easily treatable by dose reduction or drug holiday. The underlying concept… CONTINUE READING
    37 Citations
    The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
    • George J. Brewer
    • Medicine
    • Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements
    • 2014
    • 26
    The use of copper-lowering therapy with tetrathiomolybdate in medicine
    • 20
    Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation
    • G. Brewer
    • Medicine
    • Journal of cellular and molecular medicine
    • 2003
    • 64
    Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm
    • 23
    Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats
    • 37
    Ammonium tetrathiomolybdate treatment of copper‐associated hepatopathy in dogs
    • 1
    • Highly Influenced
    Anticopper therapy against cancer and diseases of inflammation and fibrosis.
    • 101


    Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
    • G. Brewer, R. Dick, +10 authors S. Merajver
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2000
    • 278
    • PDF
    Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease
    • G. Brewer
    • Biology, Medicine
    • Experimental biology and medicine
    • 2001
    • 151
    Radiotherapy and antiangiogenic TM in lung cancer.
    • 78
    Angiogenesis and Cancer Control: From Concept to Therapeutic Trial.
    • Brem
    • Medicine
    • Cancer control : journal of the Moffitt Cancer Center
    • 1999
    • 140
    • Highly Influential
    • PDF
    Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate.
    • 70
    Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells.
    • 91
    • PDF
    Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats.
    • 69
    Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy
    • 149
    • PDF
    Penicillamine, a new oral therapy for Wilson's disease.
    • J. Walshe
    • Medicine
    • The American journal of medicine
    • 1956
    • 588